RocketTickers

REGENXBIO Announces FDA Clearance of IND for Phase II Trial of R

Long
NASDAQ:RGNX   REGENXBIO Inc.
RGNX: REGENXBIO Inc.
2020-08-25 07:00:00
REGENXBIO Announces FDA Clearance of IND for Phase II Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.